Glycogen Phosphorylase Inhibitors

Title: Glycogen Phosphorylase Inhibitors

Volume: 6 Issue: 8

Author(s): Brad R. Henke and Steven M. Sparks

Affiliation:

Keywords: Glycogen Phosphorylase, Glycogenolysis, Type 2 diabetes, Hepatic glucose output, glycogen phosphorylase inhibitors

Abstract: Type 2 diabetes is a complex metabolic disease with hyperglycemia as its recognizable hallmark. Hepatic glucose output is elevated in Type 2 diabetic patients, and evidence suggests drugs which lower hepatic glucose production are effective antihyperglycemic agents. Glycogenolysis, which is the release of monomeric glucose from its polymeric storage form called glycogen, is a key contributor to hepatic glucose output. Glycogen phosphorylase is the enzyme that catalyzes this process. This review covers advances in the design of small molecule inhibitors of this enzyme, their biological activity, and their potential as effective antihyperglycemic agents for the treatment of Type 2 diabetes.

Cite this article as:

Henke R. Brad and Sparks M. Steven, Glycogen Phosphorylase Inhibitors, Mini-Reviews in Medicinal Chemistry 2006; 6 (8) . https://dx.doi.org/10.2174/138955706777934991